Health Care • Biotechnology: Pharmaceutical Preparations
$13.59 ▲ +0.27
(+2.03%)
MKT CAP: $2.37B • VOL: 34.3K
52W L $10 52W H $16
HCM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $548.5M | $630.2M | $838.0M |
| YoY Revenue Growth % | -13.0% | -24.8% | — |
| Gross Profit | $212.2M | $281.3M | — |
| Gross Margin % | 38.7% | 44.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$39.2M | -$43.7M | $18.4M |
| Operating Margin % | -7.1% | -6.9% | 2.2% |
| Net Income (GAAP) | $456.9M | $37.7M | $100.8M |
| EBITDA (Normalized) | -$27.8M | -$29.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$64.7M | $497.0K | $219.3M |
| Capital Expenditures (CapEx) | $14.1M | $17.9M | — |
| Free Cash Flow (FCF) | -$78.8M | -$17.4M | $219.3M |
| FCF Margin % | -14.4% | -2.8% | 26.2% |
| Return on Invested Capital (ROIC %) | -2.5% | -5.2% | — |
| Cash & Short-Term Equivalents | $71.3M | $154.0M | — |
| Total Debt (Short + Long Term) | $68.2M | $59.4M | — |
| Total Stockholders' Equity | $1.24B | $759.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HCM.